Shuttle Pharmaceuticals Inc (SHPH) - Total Assets
Based on the latest financial reports, Shuttle Pharmaceuticals Inc (SHPH) holds total assets worth $11.81 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
Shuttle Pharmaceuticals Inc - Total Assets Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's total assets have evolved over time, based on quarterly financial data. Also see SHPH market cap for the company's overall valuation and market capitalisation.
Shuttle Pharmaceuticals Inc - Asset Composition Analysis
Current Asset Composition (December 2025)
Shuttle Pharmaceuticals Inc's total assets of $11.81 Million consist of 4.8% current assets and 95.2% non-current assets. Review how much debt does Shuttle Pharmaceuticals Inc carry to assess the company's total debt and financial obligations.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 3.2% |
| Accounts Receivable | $0.00 | 0.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $9.84 Million | 93.9% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2017–2025)
This chart illustrates how Shuttle Pharmaceuticals Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See current stock price of Shuttle Pharmaceuticals Inc for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Shuttle Pharmaceuticals Inc's current assets represent 4.8% of total assets in 2025, a decrease from 84.5% in 2017.
- Cash Position: Cash and equivalents constituted 3.2% of total assets in 2025, down from 41.8% in 2017.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 93.0% of total assets, an increase from 0.0% in 2017.
- Asset Diversification: The largest asset category is intangible assets at 93.9% of total assets.
Shuttle Pharmaceuticals Inc Competitors by Total Assets
Key competitors of Shuttle Pharmaceuticals Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Kamada
TA:KMDA
|
Israel | ILA377.21 Million |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Viatris Inc
NASDAQ:VTRS
|
USA | $35.04 Billion |
|
Takeda Pharmaceutical Company Limited
F:TKDA
|
Germany | €15.41 Trillion |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603
|
China | CN¥14.18 Billion |
|
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
|
China | CN¥10.21 Billion |
|
Yipinhong Pharmaceutical Co Ltd Class A
SHE:300723
|
China | CN¥4.49 Billion |
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
USA | $199.45 Million |
Shuttle Pharmaceuticals Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.30 | 2.78 | 0.23 |
| Quick Ratio | 0.30 | 2.78 | 0.23 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-5.84 Million | $3.18 Million | $-1.71 Million |
Shuttle Pharmaceuticals Inc - Advanced Valuation Insights
This section examines the relationship between Shuttle Pharmaceuticals Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.61 |
| Latest Market Cap to Assets Ratio | 0.19 |
| Asset Growth Rate (YoY) | 318.0% |
| Total Assets | $10.48 Million |
| Market Capitalization | $1.98 Million USD |
Valuation Analysis
Below Book Valuation: The market values Shuttle Pharmaceuticals Inc's assets below their book value (0.19x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Shuttle Pharmaceuticals Inc's assets grew by 318.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Shuttle Pharmaceuticals Inc (2017–2025)
The table below shows the annual total assets of Shuttle Pharmaceuticals Inc from 2017 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $10.48 Million | +317.99% |
| 2024-12-31 | $2.51 Million | -57.89% |
| 2023-12-31 | $5.95 Million | -31.22% |
| 2022-12-31 | $8.65 Million | +1227.96% |
| 2021-12-31 | $651.64K | +19.78% |
| 2020-12-31 | $544.05K | -12.43% |
| 2018-12-31 | $621.27K | +412.19% |
| 2017-12-31 | $121.30K | -- |
About Shuttle Pharmaceuticals Inc
Shuttle Pharmaceuticals Holdings, Inc., a clinical stage pharmaceutical company, develops novel therapies to treat cancers. It owns a pharmaceutical software artificial intelligence (AI) driven platform for molecular discovery and early-stage drug development. The company was founded in 2012 and is headquartered in Gaithersburg, Maryland.